Henan Taloph Pharmaceutical Stock Co (SHSE:600222) Altman Z2-Score: 2.19 (As of Jul. 19, 2026) — 13% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600222 Henan Taloph Pharmaceutical Stock Co Ltd SHSE:600222
58 GF Score
Price ¥7.45
GF Value ¥4.91
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Henan Taloph Pharmaceutical Stock Co Altman Z2-Score?

Henan Taloph Pharmaceutical Stock Co SHSE:600222 -5.93% 58 Altman Z2-Score is 2.19 as of Jul. 19, 2026, which is 13% above its 10-year median of 1.93. GuruFocus rates SHSE:600222 with a GF Score™ of 58/100 and a GF Value™ of ¥4.91 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 996 Drug Manufacturers companies, Henan Taloph Pharmaceutical Stock Co ranks worse than 64.66% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Henan Taloph Pharmaceutical Stock Co has a Altman Z2-Score of 2.19, indicating it is in Grey Zones. This implies that Henan Taloph Pharmaceutical Stock Co is in some kind of financial stress. If it is below 1.1, the company may face bankrupcy risk.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Henan Taloph Pharmaceutical Stock Co's Altman Z2-Score or its related term are showing as below:

SHSE:600222' s Altman Z2-Score Range Over the Past 10 Years
Min: 0.93   Med: 1.93   Max: 3.86
Current: 2.19

During the past 13 years, Henan Taloph Pharmaceutical Stock Co's highest Altman Z2-Score was 3.86. The lowest was 0.93. And the median was 1.93.


Henan Taloph Pharmaceutical Stock Co  (SHSE:600222) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Henan Taloph Pharmaceutical Stock Co Altman Z2-Score Related Terms


Henan Taloph Pharmaceutical Stock Co Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for Henan Taloph Pharmaceutical Stock Co's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Henan Taloph Pharmaceutical Stock Co Altman Z2-Score Chart

Henan Taloph Pharmaceutical Stock Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.69 1.51 1.87 1.52 1.89

Henan Taloph Pharmaceutical Stock Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.68 2.16 1.77 1.89 2.19

SHSE:600222 vs ZTS, UTHR: Altman Z2-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Henan Taloph Pharmaceutical Stock Co's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Henan Taloph Pharmaceutical Stock Co Altman Z2-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Henan Taloph Pharmaceutical Stock Co's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Henan Taloph Pharmaceutical Stock Co's Altman Z2-Score falls into.


SHSE:600222
58GF Score
Henan Taloph Pharmaceutical Stock Co Ltd SHSE:600222
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Henan Taloph Pharmaceutical Stock Co Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Henan Taloph Pharmaceutical Stock Co's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.1225+3.26*0.0942+6.72*0.036+1.05*0.7987
=2.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2026:
Total Assets was ¥3,675 Mil.
Total Current Assets was ¥2,187 Mil.
Total Current Liabilities was ¥1,737 Mil.
Retained Earnings was ¥346 Mil.
Pre-Tax Income was 2.497 + 43.205 + 9.942 + 21.713 = ¥77 Mil.
Interest Expense was -13.977 + -14.071 + -14.836 + -12.175 = ¥-55 Mil.
Total Liabilities was ¥2,011 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(2187.04 - 1736.835)/3675.222
=0.1225

X2=Retained Earnings/Total Assets
=346.135/3675.222
=0.0942

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(77.357 - -55.059)/3675.222
=0.036

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(1606.252 - 0)/2011.067
=0.7987

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Henan Taloph Pharmaceutical Stock Co has a Altman Z2-Score of 2.19 indicating it is in Grey Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of 2.19 mean?
Henan Taloph Pharmaceutical Stock Co (SHSE:600222) has a Altman Z2-Score of 2.19 as of Jul. 19, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Henan Taloph Pharmaceutical Stock Co and its competitors. This is 13% above median its historical median of 1.93. Over the past decade, Henan Taloph Pharmaceutical Stock Co's Altman Z2-Score has ranged from 0.93 to 3.86. According to the industry distribution chart, Henan Taloph Pharmaceutical Stock Co ranks #644 out of 996 companies in the Drug Manufacturers industry, placing it in the top 64.7%.
Is Henan Taloph Pharmaceutical Stock Co's Altman Z2-Score too high?
Henan Taloph Pharmaceutical Stock Co's current Altman Z2-Score of 2.19 is 13% above median its 10-year median of 1.93. Over the past 10 years, this metric has ranged from a low of 0.93 to a high of 3.86. The Drug Manufacturers industry median Altman Z2-Score is 3.88. Henan Taloph Pharmaceutical Stock Co's value of 2.19 is 43.6% below this industry median. Based on the distribution chart, Henan Taloph Pharmaceutical Stock Co ranks #644 out of 996 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Henan Taloph Pharmaceutical Stock Co has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Henan Taloph Pharmaceutical Stock Co's Altman Z2-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Henan Taloph Pharmaceutical Stock Co ranks #644 out of 996 companies for Altman Z2-Score. This places Henan Taloph Pharmaceutical Stock Co in the lower half of its industry. The industry median Altman Z2-Score is 3.88. Henan Taloph Pharmaceutical Stock Co's value of 2.19 is 43.6% below this benchmark. Historically, Henan Taloph Pharmaceutical Stock Co's own Altman Z2-Score has ranged from 0.93 to 3.86 over the past decade. While the company's 10-year median is 1.93 vs. the industry median of 3.88, Henan Taloph Pharmaceutical Stock Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Drug Manufacturers company?
The median Altman Z2-Score among Drug Manufacturers companies is 3.88, based on 996 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Henan Taloph Pharmaceutical Stock Co's current Altman Z2-Score of 2.19 is 43.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Henan Taloph Pharmaceutical Stock Co and its competitors. For the Drug Manufacturers industry, the median Altman Z2-Score is 3.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Henan Taloph Pharmaceutical Stock Co's current Altman Z2-Score is 2.19, which is 13% above median its own 10-year median of 1.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Henan Taloph Pharmaceutical Stock Co stock overvalued right now?
Based on GuruFocus' analysis, Henan Taloph Pharmaceutical Stock Co (SHSE:600222) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥4.91, compared to a current price of ¥7.45 — trading 51.7% above its estimated fair value. The current Altman Z2-Score is 2.19, which is 13% above median its 10-year median of 1.93 and 43.6% below the Drug Manufacturers industry median of 3.88. Henan Taloph Pharmaceutical Stock Co's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Henan Taloph Pharmaceutical Stock Co (SHSE:600222), the current Altman Z2-Score is 2.19 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Henan Taloph Pharmaceutical Stock Co (SHSE:600222) Overvalued in 2026?

Based on GuruFocus' analysis, Henan Taloph Pharmaceutical Stock Co stock appears to be overvalued. The current stock price of ¥7.45 is trading 51.7% above its estimated GF Value™ of ¥4.91. GuruFocus considers Henan Taloph Pharmaceutical Stock Co to be Significantly Overvalued.

Key valuation signals for SHSE:600222:

  • Altman Z2-Score: 2.19 (13% above median its 10-year median of 1.93)
  • GF Value™: ¥4.91 vs. price of ¥7.45 (51.7% above fair value)
  • GF Score™: 58/100 with 6 warning signs
  • Industry Position: 43.6% below the Drug Manufacturers median (#644 of 996)

No single metric tells the full story. See the SHSE:600222 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Henan Taloph Pharmaceutical Stock Co Business Description

Address No. 8, Jinsuo Road, High-tech Industrial Development Zone, Henan Province, Zhengzhou, CHN, 450001
Henan Taloph Pharmaceutical Stock Co Ltd is a Chinese company engaged in pharmaceutical manufacturing and pharmaceutical research and development services, including pharmaceutical preparations, Chinese herbal medicine slices, and pharmaceutical research and development services. The company's pharmaceutical preparation business is mainly based on oral Chinese medicine preparations, and its treatment areas cover the respiratory system, cardiovascular and cerebrovascular system, digestive system, and nervous system.
58GF Score

Get the complete analysis for SHSE:600222

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥7.45
Price
¥4.91
GF Value